TG Therapeutics (NASDAQ: TGTX) reported Q3 EPS of ($0.50), $0.19 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $38.1 thousand versus the consensus estimate of $30 thousand.

Cash, cash equivalents, investment securities, and interest receivable were $60.7 million as of September 30, 2016.

For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.